Techno Medica (6678) Q4 2026 earnings summary

Executive summary

• Revenue increased 13.4% year-over-year to ¥11,236 million, driven by strong domestic and overseas sales of blood collection tube preparation systems.

• Operating profit rose 28.3% to ¥1,668 million and net profit grew 6.6% to ¥1,070 million, despite special losses from discontinued product lines.

• The company maintained a high equity ratio of 80.2% and ended the year with ¥8,976 million in cash and equivalents.

Financial highlights

• Gross profit increased 6.4% to ¥5,243 million, while SG&A expenses decreased 1.5% due to lower R&D costs.

• Cash flow from operations was ¥1,100 million, up ¥123 million year-over-year; investing and financing cash flows were negative due to asset purchases and share buybacks.

• Dividend per share doubled to ¥129, with total dividends paid of ¥859 million and a payout ratio of 83.1%.

Outlook and guidance

• For FY2027, revenue is forecast to decline 8.3% to ¥10,300 million, with operating profit expected to fall 34.1% to ¥1,100 million and net profit to ¥770 million.

• Management cites a challenging environment for capital investment in medical devices due to cost pressures and cautious spending by healthcare institutions.